← Leaderboards
Steven Grant
University Of Tx Md Anderson Can Ctr
$1,384,176
Attributed
$1,384,176
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $283.7K · FY2010–14$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,384,176 · 1
By mechanism
P50$1,384,176 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Michael W Andreeff$17,991,896
- Kapil N. Bhalla$16,921,043
- Khandan Keyomarsi$13,000,468
- Dihua Yu$18,443,603
- Srdan Verstovsek$1,168,238
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsCyclin-Dependent Kinase InhibitorAdherence (Attribute)ApoptosisClinically RelevantComplexBik GeneBaseB Lymphoid MalignancyBone Marrow CellsBortezomibApoptoticCd34 GeneBcl2l11 GeneCell AdhesionCell CycleCell DeathBirc4 GeneCellsCell SurvivalCell TransformationCessation Of LifeChemosensitizationCyclins
Grant awards (5)
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTS$269,577
P50 · FY2014 · CA · contact PI
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTS$279,543
P50 · FY2013 · CA · contact PI
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTS$283,681
P50 · FY2012 · CA · contact PI
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTS$269,408
P50 · FY2011 · CA · contact PI
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTS$281,967
P50 · FY2010 · CA · contact PI